Search

everythinglearnresearchcommunity

for

Search:↓

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Erlotinib can cause hair loss as a side effect.

Imatinib can cause hair loss due to lichen planopilaris.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Gefitinib can cause rare scarring hair loss.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Gefitinib therapy can cause unusual hair growth on the nose.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

A woman's hair turned white after taking a cancer drug called dasatinib.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Gefitinib can cause hair loss without scarring.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.